Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia californica pollen extract is a biological allergen extract derived from the pollen of the California Sagebrush (*Artemisia californica*), a shrub native to the coastal regions of California. It is primarily utilized in clinical allergy practice for both diagnostic and therapeutic purposes. As a diagnostic agent, it is used in percutaneous or intradermal skin testing to identify patients with Type I hypersensitivity to California Sagebrush pollen. As a therapeutic agent, it is employed in allergen immunotherapy (hyposensitization therapy), where gradually increasing doses of the extract are administered subcutaneously to induce immunological tolerance. The mechanism of action involves shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated response, leading to the production of "blocking" IgG4 antibodies and a reduction in allergen-specific IgE-mediated mast cell degranulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia californica pollen extract.